Asset Details
Do you wish to reserve the book?
Combination therapy using nitro compounds improves the efficacy of experimental Chagas disease treatment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Combination therapy using nitro compounds improves the efficacy of experimental Chagas disease treatment
Do you wish to request the book?
Combination therapy using nitro compounds improves the efficacy of experimental Chagas disease treatment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Combination therapy using nitro compounds improves the efficacy of experimental Chagas disease treatment
2021
Overview
Drug combinations have been evaluated for Chagas disease in an attempt to improve efficacy and safety. In this line, the objective of this work is to assess the effects of treatment with nitro drugs combinations using benznidazole (BZ) or nifurtimox (NFX) plus the sulfone metabolite of fexinidazole (fex-SFN) in vitro and in vivo on Trypanosoma cruzi infection. The in vitro interaction of fex-SFN and BZ or NFX against infected H9c2 cells by the Y strain was classified as an additive (0.5⩾ΣFIC<4), suggesting the possibility of a dose reduction in the in vivo T. cruzi infection. Next, the effect of combining suboptimal doses was assessed in an acute model of murine T. cruzi infection. Drug combinations led to a faster suppression of parasitemia than monotherapies. Also, the associations led to higher cure levels than those in the reference treatment BZ 100 mg day−1 (57.1%) (i.e. 83.3% with BZ/fex-SFN and 75% with NFX/fex-SFN). Importantly, toxic effects resulting from the associations were not observed, according to weight gain and hepatic enzyme levels in the serum of experimental animals. Taken together, this study is a starting point to explore the potential effects of nitro drugs combinations in preclinical models of kinetoplastid-related infections.
Publisher
Cambridge University Press
Subject
/ Chagas Disease - drug therapy
/ Drugs
/ enzymes
/ Female
/ Humans
/ Mice
/ Neglected Diseases - drug therapy
/ Nifurtimox - adverse effects
/ Nifurtimox - therapeutic use
/ Nitro Compounds - adverse effects
/ Nitro Compounds - therapeutic use
/ Nitroimidazoles - adverse effects
/ Nitroimidazoles - metabolism
/ Nitroimidazoles - therapeutic use
/ Real-Time Polymerase Chain Reaction
/ toxicity
